Figure 1.

Effects of XENT and ENZA, alone or in combination, on prostate cancer cells: A–E) Cells were cultivated in medium containing FBS, in the absence of androgen or growth factor supplementation, and cell viability was measured using the CellTiter-Glo^® Luminescent Assay after treatment with indicated concentrations of XENT and ENZA for 5 days (DuCaP, MDA PCa 2b), 7 days (LNCaP), or 10 days (VCaP, PC-3). F) VCaP cell proliferation was determined by measuring thymidine incorporation in a 5 day assay in FBS-containing medium. G) VCaP cells were either left untransfected or were transfected with PTEN small interfering RNA (siRNA), and were treated with XENT, ENZA, or XENT+ENZA. Cell viability was measured after 3 days using the CellTiter- Glo^® Assay. Results are represented as percentage of inhibition, relative to untreated control, with or without PTEN siRNA, respectively. Data are expressed as mean ± standard deviation for n = 3. P values were calculated using pairwise t-tests (adjusted for multiplicity) following a one-way analysis of variance.